2023
Atezolizumab for Advanced Alveolar Soft Part Sarcoma
Chen A, Sharon E, O'Sullivan-Coyne G, Moore N, Foster J, Hu J, Van Tine B, Conley A, Read W, Riedel R, Burgess M, Glod J, Davis E, Merriam P, Naqash A, Fino K, Miller B, Wilsker D, Begum A, Ferry-Galow K, Deshpande H, Schwartz G, Ladle B, Okuno S, Beck J, Chen J, Takebe N, Fogli L, Rosenberger C, Parchment R, Doroshow J. Atezolizumab for Advanced Alveolar Soft Part Sarcoma. New England Journal Of Medicine 2023, 389: 911-921. PMID: 37672694, PMCID: PMC10729808, DOI: 10.1056/nejmoa2303383.Peer-Reviewed Original ResearchConceptsAdvanced alveolar soft part sarcomaAlveolar soft part sarcomaProgression-free survivalSoft part sarcomaObjective responsePart sarcomaMedian progression-free survivalTreatment-related grade 4Rare soft tissue sarcomaData cutoff dateImmune checkpoint inhibitorsPhase 2 studyResponse Evaluation CriteriaThird of patientsDuration of responseSoft tissue sarcomasYears of treatmentCheckpoint inhibitorsAdverse eventsMedian durationPartial responseComplete responseDeath-1PD-L1Pediatric patients
2022
Hemophagocytic Lymphohistiocytosis as a complication of immune checkpoint inhibitor therapy for sarcoma
Kenworthy C, Di M, Deshpande H. Hemophagocytic Lymphohistiocytosis as a complication of immune checkpoint inhibitor therapy for sarcoma. Current Problems In Cancer Case Reports 2022, 8: 100202. DOI: 10.1016/j.cpccr.2022.100202.Peer-Reviewed Original ResearchNatural killer (NK) cell activityImmune checkpoint inhibitor therapyImmune checkpoint inhibitor useSoluble IL-2 receptorCheckpoint inhibitor useImmune checkpoint inhibitorsCheckpoint inhibitor therapyCoffee-ground emesisIL-2 receptorPelvic osteosarcomaCheckpoint inhibitorsElevated ferritinInhibitor therapyHemophagocytic lymphohistiocytosisMetastatic sarcomaFailed treatmentElevated triglyceridesInhibitor useSarcoma patientsConventional therapyCell activationCancer treatmentPatientsSarcomaTherapy